Current Edition


Lilly and Boehringer’s Jardiance, trailing AZ’s Farxiga in chronic kidney disease, posts efficacy win

After a series of wins in heart failure, Eli Lilly and Boehringer Ingelheim are pumping the breaks on a late-stage Jardiance trial in chronic kidney …

Continue Reading →
Boehringer Ingelheim

Lilly and Boehringer’s Jardiance shows benefits for those with ‘intimately linked’ heart failure and kidney disease

Heart failure and chronic kidney disease often go hand in hand. And when they do, the risk of death and hospitalization increase. A new analysis …

Continue Reading →

Novo’s oral semaglutide outperforms Jardiance in late-stage study

Danish drugmaker Novo Nordisk said Tuesday its PIONEER 2 study testing oral semaglutide in patients with type 2 diabetes met its primary objective, showing a …

Continue Reading →